Skip to main content
. 2022 May 21;28:920–934. doi: 10.1016/j.omtn.2022.05.033

Figure 3.

Figure 3

Exogenous RPS4XL treatment of PASMCs inhibits hypoxia-induced pyroptosis

(A) Synthetic sequence of the exogenous peptide RPS4XL. (B) LDH release assay using PASMCs treated with 5 μg/mL, 7.5 μg/mL, or 10 μg/mL exogenous RPS4XL under hypoxia. (C) PI staining in PASMCs treated with 10 μg/mL RPS4XL under hypoxia (scale bar, 50 μm). Western blotting analysis of (D) c-caspase-1, (E) NLRP3, ASC, IL-1β, and IL-18 in PASMCs treated with 5 μg/mL, 7.5 μg/mL, or 10 μg/mL RPS4XL under hypoxia. FLAG was used as a negative control. All values are represented as the mean ± SEM (∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.0001; n ≥ 3). NOR, normoxia; HYP, hypoxia.